share_log

After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact

After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact

經過六年的合作，武田退出了微生物組藥物協議
Benzinga Real-time News ·  2022/08/26 07:38
  • Finch Therapeutics Group Inc (NASDAQ:FNCH) will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Ltd (NYSE:TAK). 
  • Following a review of its pipeline, Takeda will terminate its collaboration with Finch, effective November 17, 2022, resulting in the return to Finch of worldwide rights to develop and commercialize FIN-524, FIN-525, and any other microbiome product candidates for inflammatory bowel disease (IBD). 
  • Also Read: Takeda To Lead Finch-Partnered Microbiome IBD Drug.
  • "We are currently conducting a review of our portfolio and assessing the financial and strategic impact of the discontinuation of our collaboration with Takeda," said Mark Smith, CEO of Finch Therapeutics. 
  • Finch has received more than $44 million from Takeda during the collaboration, including an upfront payment of $10 million, $4 million in milestone payments, and more than $30 million in reimbursement of R&D expenses. 
  • Upon termination, Finch will receive a royalty-free license to all data and intellectual property generated during the collaboration.
  • FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties.
  • Price Action: FNCH shares closed at $2.64, and TAK stock closed at $14.02 on Thursday.
  • 芬奇治療集團公司(納斯達克股票代碼：FNCH)將從以下公司重新獲得FIN-524(以前稱為TAK-524)和FIN-525的全部開發和商業權武田藥品株式會社(紐約證券交易所股票代碼：Tak)。
  • 在對其流水線進行審查後，武田將從2022年11月17日起終止與芬奇的合作，導致芬奇重新獲得開發和商業化FIN-524、FIN-525和任何其他用於炎症性腸病(IBD)的微生物組產品的全球權利。
  • 另請閲讀： 武田將領導與Finch合作的微生物組IBD藥物.
  • “我們目前正在對我們的投資組合進行審查，並評估我們終止與武田合作的財務和戰略影響，”芬奇治療公司首席執行官馬克·史密斯説。
  • 芬奇在合作期間從武田收到了超過4400萬美元，包括1000萬美元的預付款，400萬美元的里程碑付款，以及3000多萬美元的研發費用報銷。
  • 終止後，Finch將獲得合作期間產生的所有數據和知識產權的免版税許可。
  • FIN-524和FIN-525是研究中的、口服給藥的靶向微生物組產品，由可能具有免疫調節特性的細菌菌株組成。
  • 價格行動：FNCH股價週四收於2.64美元，TAK股價收於14.02美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論